Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 287

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 287
---
 from other drugs currently on the market or that may be approved in the future. The number of women with PPD, the unmet need for additional treatment options for women with PPD, and the potential market for ZURZUVAE may be significantly smaller than we expect, or we may encounter other market-related issues in the commercialization of ZURZUVAE for the treatment of women with PPD, including as a result of the price we charge. We and our collaboration partner, Biogen, may not be applying the optimal resources to the launch of ZURZUVAE or we or Biogen may not be able or willing to scale our resources at the right time or at an effective level. 

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

(a)    Sales of Unregistered Securities.

None.

Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Mine Safety Disclosures

None.

Item 5.    Other Information

(a)     None.

(b)    None.

(c)    Insider Trading Arrangements and Policies.

63

The table below lists the insider trading arrangements adopted or terminated during the third quarter of 2025:Name and Title of Director or OfficerRule 10b5-1 Trading Arrangement(1)Trading Arrangement Adopted or TerminatedDate of Adoption or TerminationDuration of Trading ArrangementAggregate Number of Securities to be Purchased Pursuant to Trading ArrangementAggregate Number of Securities to be Sold Pursuant to Trading ArrangementFrank Mottola SVP, Chief Technology Operations Officer YesAdoptedSeptember 15, 2025January 14, 2026—20,000____________________________________(1) Indicates whether the trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).(2)This trading arrangement covers the exercise and sale of stock options, with a portion of such sales limited to an amount reasonably estimated such that the net proceeds from the sale are sufficient to cover the exercise cost and taxes associated with the exercise of the stock options.

Item 6.    Exhibits

The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:ExhibitNumberDescription10.1††Biogen Collaboration and License Agreement by and among Sage Therapeutics, Inc., Biogen MA Inc. and Biogen International GmbH, dated November 27, 2020 (